within Pharmacolibrary.Drugs.ATC.A;

model A10BK04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 0.18666666666666665,
    adminDuration  = 600,
    adminMass      = 0.015,
    adminCount     = 1,
    Vd             = 0.0855,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011683333333333332,
    Tlag           = 60
  );

  annotation(Documentation(
    info ="<html><body><p>Ertugliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus to improve glycemic control. It is approved for clinical use and generally administered orally as a tablet.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for healthy adult subjects (both sexes), after single and multiple oral doses under fasted and fed conditions.</p><h4>References</h4><ol><li>Yinhua Li, Gianluca Nucci, Yuichi Yamamoto, Daryl J Fediuk, Vaishali Sahasrabudhe,Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects.,Clinical pharmacology in drug development,2021<a href='https://pubmed.ncbi.nlm.nih.gov/33434408/'>https://pubmed.ncbi.nlm.nih.gov/33434408/</a></li><li>Ranjeet Prasad Dash, R Jayachandra Babu, Nuggehally R Srinivas,Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview.,Xenobiotica; the fate of foreign compounds in biological systems,2017<a href='https://pubmed.ncbi.nlm.nih.gov/27718782/'>https://pubmed.ncbi.nlm.nih.gov/27718782/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BK04;
